ELSEVIER

Atherosclerosis 131 (1997) 266–269

ATHEROSCLEROSIS

Author index

Volume 131 (1997)

Abbott, D., A. Daher, P. Manwaring, L.G. Howes, Simvastatin reduces forearm vascular responsiveness to norepinephrine **131**, 263
Absher, P.M., D.J. Schneider, L.C. Baldor, J.C. Russell, B.E. Sobel, Increased proliferation of explanted vascular smooth muscle cells: a marker presaging atherogenesis **131**, 187
Akishita, M., see Yoo, H.J. **131**, 167
Alavi, M.Z., see Wang, H. **131**, 141
Alpérovitch, A., see Bizbiz, L. **131**, 73
Andreasen, P.H., see Jensen, H.K. **131**, 67
Andresen, B.S., see Jensen, H.K. **131**, 67
Arveiler, D., see Luc, G. **131**, 257

Bakker-Arkema, R.G., J. Best, R. Fayyad, T.M. Heinonen, A.D. Marais, J.W. Nawrocki, D.M. Black, A brief review paper of the efficacy and safety of atorvastatin in early clinical trials **131**, 17
Baldor, L.C., see Absher, P.M. **131**, 187
Bard, J.-M., see Luc, G. **131**, 257
Berenson, G.S., see Madhavan, M. **131**, 107
Best, J., see Bakker-Arkema, R.G. **131**, 17
Bizbiz, L., A. Alpérovitch, the EVA Group, Aging of the vascular wall: serum concentration of elastin peptides and elastase inhibitors in relation to cardiovascular risk factors. The EVA study **131**, 73
Black, D.M., see Bakker-Arkema, R.G. **131**, 17
Bolund, L., see Jensen, H.K. **131**, 67
Bräutigam, C., see Bräutigam, R. **131**, 97
Bräutigam, R., C. Bräutigam, R. Lorenz, W.O. Richter, B. Engelmann, Arachidonic acid of platelet phospholipids is decreased after extracorporeal removal of plasma low density lipoproteins in patients with familial hypercholesterolemia **131**, 97
Brizzi, P., see Maioli, M. **131**, 127
Brunet, S., see Guertin, F. **131**, 35

Cai, W.-j., B. Devaux, W. Schaper, J. Schaper, The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions **131**, 177
Callender, M.E., see O'Kane, M.J. **131**, 203
Cambien, F., see Luc, G. **131**, 257
Cercek, B., M. Yamashita, P. Dimayuga, J. Zhu, M.C. Fishbein, S. Kaul, P.K. Shah, J. Nilsson, J. Regnstrom, Nuclear factor-κB activity and arterial response to balloon injury **131**, 59
Chambless, L.E., see Zheng, Z.-J. **131**, 115
Chan, J.C.N., see Ko, G.T.C. **131**, 211
Chan, P.-c., C. Jones, R. Lafrenière, H.G. Parsons, Surface expression of low density lipoprotein receptor in EBV-transformed lymphocytes: characterization and use for studying familial hypercholesterolemia **131**, 149
Chapman, M.J., see Guerin, M. **131**, 85
Chevet, D., see Guerin, M. **131**, 85
Chow, C.-C., see Ko, G.T.C. **131**, 211
Ciccarese, M., see Maioli, M. **131**, 127
Cockram, C.S., see Ko, G.T.C. **131**, 211
Crook, M.A., N.J. Miller, Serum antioxidant status in hypobetalipoproteinaemia **131**, 135

Dachet, C., see Guerin, M. **131**, 85
Daher, A., see Abbott, D. **131**, 263
Devaux, B., see Cai, W.-j. **131**, 177
Dimayuga, P., see Cercek, B. **131**, 59
Dobs, A., see Zheng, Z.-J. **131**, 115
Doi, H., see Ota, Y. **131**, 195
Dolphin, P.J., see Guerin, M. **131**, 85
Donegà, P., see Maioli, M. **131**, 127
Ducimetiere, P., see Luc, G. **131**, 257

Elneihoum, A.M., P. Falke, B. Hedblad, F. Lindgärde, K. Ohlsson, Leukocyte activation in atherosclerosis: correlation with risk factors **131**, 79
Engelmann, B., see Bräutigam, R. **131**, 97
Eto, M., see Yoo, H.J. **131**, 167
Evans, A., see Luc, G. **131**, 257
Evans, G.W., see Zheng, Z.-J. **131**, 115

Falke, P., see Elneihoum, A.M. **131**, 79

Fayyad, R., see Bakker-Arkema, R.G. **131**, 17
Fellin, R., see Maioli, M. **131**, 127
Fievet, C., see Luc, G. **131**, 257
Fishbein, M.C., see Cercek, B. **131**, 59
Fowkes, F.G.R., see Mowat, B.F. **131**, 161
Færgeman, O., see Jensen, H.K. **131**, 67
Fruchart, J.-C., see Luc, G. **131**, 257
Funahashi, T., see Yanagi, K. **131**, 49

Geiss, H.C., see Ritter, M.M. **131**, 243
Gewitsch, J., see Ritter, M.M. **131**, 243
Goulinet, S., see Guerin, M. **131**, 85
Gregersen, N., see Jensen, H.K. **131**, 67
Guerin, M., C. Dachet, S. Goulinet, D. Chevet, P.J. Dolphin, M.J. Chapman, M. Rouis, Familial lecithin:cholesterol acyltransferase deficiency: molecular analysis of a compound heterozygote: LCAT ($Arg^{147} \rightarrow Trp$) and LCAT ($Tyr^{171} \rightarrow$ Stop) **131**, 85
Guertin, F., S. Brunet, D. Lairon, E. Levy, Oxidative tyrosylation of high density lipoprotein impairs biliary sterol secretion in rats **131**, 35

Hansen, P.S., see Jensen, H.K. **131**, 67
Harmon, D.L., D. McMaster, D.C. Shields, A.S. Whitehead, I.M. Rea, MTHFR thermolabile genotype frequencies and longevity in Northern Ireland **131**, 137
Hashimoto, M., see Yoo, H.J. **131**, 167
Hayakari, M., see Tamasawa, N. **131**, 237
Heath, F., see Jensen, H.K. **131**, 67
Hedblad, B., see Elneihoum, A.M. **131**, 79
Heinonen, T.M., see Bakker-Arkema, R.G. **131**, 17
Heiss, G., see Zheng, Z.-J. **131**, 115
Hirai, A., see Saito, J. **131**, 219
Hirano, K.-i., see Yanagi, K. **131**, 49
Hiraoka, H., see Yanagi, K. **131**, 49
Holst, H., see Jensen, H.K. **131**, 67
Hornstra, G., A.D.M. Kester, Effect of the dietary fat type on arterial thrombosis tendency: systematic studies with a rat model **131**, 25
Horrobin, D., see Mowat, B.F. **131**, 161
Howes, L.G., see Abbott, D. **131**, 263

Inoue, T., see Shoji, T. **131**, 229
Ishigami, M., see Yanagi, K. **131**, 49

Jensen, H.K., H. Holst, L.G. Jensen, M.M. Jørgensen, P.H. Andreasen, T.G. Jensen, B.S. Andresen, F. Heath, P.S. Hansen, S. Neve, K. Kristiansen, O. Færgeman, S. Kølvraa, L. Bolund, N. Gregersen, A common W556S mutation in the LDL receptor gene of Danish patients with familial hypercholesterolemia encodes a transport-defective protein **131**, 67
Jensen, L.G., see Jensen, H.K. **131**, 67
Jensen, T.G., see Jensen, H.K. **131**, 67
Jones, C., see Chan, P.-c. **131**, 149
Jørgensen, M.M., see Jensen, H.K. **131**, 67

Kamboh, M.I., see Saha, N. **131**, 249
Kameda-Takemura, K., see Yanagi, K. **131**, 49
Kanzaki, T., see Morisaki, N. **131**, 43
Katan, M.B., see Zock, P.L. **131**, 7
Kaul, S., see Cercek, B. **131**, 59
Kawagishi, T., see Shoji, T. **131**, 229
Kawasaki, K., see Shoji, T. **131**, 229
Kester, A.D.M., see Hornstra, G. **131**, 25
Kihara, S., see Yanagi, K. **131**, 49
Kim, S., see Yoo, H.J. **131**, 167
Kølvraa, S., see Jensen, H.K. **131**, 67
Ko, G.T.C., V.T.F. Yeung, J.C.N. Chan, C.-C. Chow, J.K.Y. Li, W.-Y. So, L.W.W. Tsang, C.S. Cockram, Plasma fibrinogen concentration in a Chinese population **131**, 211
Kozaki, K., see Yoo, H.J. **131**, 167
Kristiansen, K., see Jensen, H.K. **131**, 67
Kubo, M., see Yanagi, K. **131**, 49
Kugiyama, K., see Ota, Y. **131**, 195

Lafrenière, R., see Chan, P.-c. **131**, 149
Lairon, D., see Guertin, F. **131**, 35
Leng, G.C., see Mowat, B.F. **131**, 161
Levy, E., see Guertin, F. **131**, 35
Li, J.K.Y., see Ko, G.T.C. **131**, 211
Lindgärde, F., see Elneihoum, A.M. **131**, 79
Lorenz, R., see Bräutigam, R. **131**, 97
Luc, G., P. Ducimetiere, J.-M. Bard, D. Arveiler, A. Evans, F. Cambien, J.-C. Fruchart, C. Fievet, Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype **131**, 257
Lynch, P.L.M., see O'Kane, M.J. **131**, 203

Madhavan, M., W.A. Wattigney, S.R. Srinivasan, G.S. Berenson, Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults **131**, 107
Maioli, M., G.B. Vigna, G. Tonolo, P. Brizzi, M. Ciccarese, P. Donegà, M. Maioli, R. Fellin, Plasma lipoprotein composition, apolipoprotein(a) concentration and isoforms in β-thalassemia **131**, 127
Maioli, M., see Maioli, M. **131**, 127
Manwaring, P., see Abbott, D. **131**, 263
Marais, A.D., see Bakker-Arkema, R.G. **131**, 17
Masuda, M., see Morisaki, N. **131**, 43
Masuda, Y., see Morisaki, N. **131**, 43
Matsui, J., see Tamasawa, N. **131**, 237
Matsumura, T., see Ota, Y. **131**, 195
Matsuzawa, Y., see Yanagi, K. **131**, 49
McMaster, D., see Harmon, D.L. **131**, 137
Miller, N.J., see Crook, M.A. **131**, 135
Moore, S., see Wang, H. **131**, 141
Morii, H., see Shoji, T. **131**, 229
Morisaki, N., I. Saito, K. Tamura, J. Tashiro, M. Masuda, T. Kanzaki, S. Watanabe, Y. Masuda, Y. Saito, New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease **131**, 43

Mowat, B.F., E.R. Skinner, H.M. Wilson, G.C. Leng, F.G.R. Fowkes, D. Horrobin, Alterations in plasma lipids, lipoproteins and high density lipoprotein subfractions in peripheral arterial disease **131**, 161
Murakami, H., see Tamasawa, N. **131**, 237

Nagano, K., see Yoo, H.J. **131**, 167
Nawrocki, J.W., see Bakker-Arkema, R.G. **131**, 17
Neve, S., see Jensen, H.K. **131**, 67
Nieto, F.J., see Zheng, Z.-J. **131**, 115
Nilsson, J., see Cercek, B. **131**, 59
Nishizawa, Y., see Shoji, T. **131**, 229
Nozaki, S., see Yanagi, K. **131**, 49

Ogata, N., see Ota, Y. **131**, 195
Ohgushi, M., see Ota, Y. **131**, 195
Ohlsson, K., see Elneihoum, A.M. **131**, 79
Oka, H., see Ota, Y. **131**, 195
O'Kane, M.J., P.L.M. Lynch, M.E. Callender, E.R. Trimble, Abnormalities of serum apo A1 containing lipoprotein particles in patients with primary biliary cirrhosis **131**, 203
Ota, Y., K. Kugiyama, S. Sugiyama, M. Ohgushi, T. Matsumura, H. Doi, N. Ogata, H. Oka, H. Yasue, Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract—role of free radicals and attenuation by captopril **131**, 195
Ouchi, Y., see Yoo, H.J. **131**, 167

Parsons, H.G., see Chan, P.-c. **131**, 149

Rea, I.M., see Harmon, D.L. **131**, 137
Regnstrom, J., see Cercek, B. **131**, 59
Richter, W.O., see Bräutigam, R. **131**, 97
Richter, W.O., see Ritter, M.M. **131**, 243
Ritter, M.M., J. Gewitsch, W.O. Richter, H.C. Geiss, M.W. Wildner, P. Schwandt, Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein(a) **131**, 243
Rosamond, W.D., see Zheng, Z.-J. **131**, 115
Rouis, M., see Guerin, M. **131**, 85
Russell, J.C., see Absher, P.M. **131**, 187

Saha, N., G. Wang, S. Vasisht, M.I. Kamboh, Influence of two apo A4 polymorphisms at codons 347 and 360 on non-fasting plasma lipoprotein-lipids and apolipoproteins in asian Indians **131**, 249
Saito, I., see Morisaki, N. **131**, 43
Saito, J., T. Terano, A. Hirai, T. Shiina, Y. Tamura, Y. Saito, Mechanisms of enhanced production of PGI_2 in cultured rat vascular smooth muscle cells enriched with eicosapentaenoic acid **131**, 219
Saito, Y., see Morisaki, N. **131**, 43
Saito, Y., see Saito, J. **131**, 219
Sakai, N., see Yanagi, K. **131**, 49
Schaper, J., see Cai, W.-j. **131**, 177
Schaper, W., see Cai, W.-j. **131**, 177
Schneider, D.J., see Absher, P.M. **131**, 187
Schwandt, P., see Ritter, M.M. **131**, 243
Shah, P.K., see Cercek, B. **131**, 59
Sharrett, A.R., see Zheng, Z.-J. **131**, 115
Sheps, D.S., see Zheng, Z.-J. **131**, 115
Shields, D.C., see Harmon, D.L. **131**, 137
Shiina, T., see Saito, J. **131**, 219
Shoji, T., Y. Nishizawa, T. Kawagishi, M. Tanaka, K. Kawasaki, T. Tabata, T. Inoue, H. Morii, Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis **131**, 229
Skinner, E.R., see Mowat, B.F. **131**, 161
Sobel, B.E., see Absher, P.M. **131**, 187
So, W.-Y., see Ko, G.T.C. **131**, 211
Srinivasan, S.R., see Madhavan, M. **131**, 107
Suda, T., see Tamasawa, N. **131**, 237
Sudo, N., see Yoo, H.J. **131**, 167
Sugiyama, S., see Ota, Y. **131**, 195

Tabata, T., see Shoji, T. **131**, 229
Tamasawa, N., M. Hayakari, H. Murakami, J. Matsui, T. Suda, Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver **131**, 237
Tamura, K., see Morisaki, N. **131**, 43
Tamura, Y., see Saito, J. **131**, 219
Tanaka, M., see Shoji, T. **131**, 229
Tashiro, J., see Morisaki, N. **131**, 43
Terano, T., see Saito, J. **131**, 219
Thompson, G.R., What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? **131**, 1
Toba, K., see Yoo, H.J. **131**, 167
Tokunaga, K., see Yanagi, K. **131**, 49
Tonolo, G., see Maioli, M. **131**, 127
Trimble, E.R., see O'Kane, M.J. **131**, 203
Tsang, L.W.W., see Ko, G.T.C. **131**, 211

Vasisht, S., see Saha, N. **131**, 249
Vigna, G.B., see Maioli, M. **131**, 127

Wang, G., see Saha, N. **131**, 249
Wang, H., S. Moore, M.Z. Alavi, Expression of syndecan-1 in rabbit neointima following de-endothelialization by a balloon catheter **131**, 141
Watanabe, M., see Yoo, H.J. **131**, 167
Watanabe, S., see Morisaki, N. **131**, 43
Wattigney, W.A., see Madhavan, M. **131**, 107
Whitehead, A.S., see Harmon, D.L. **131**, 137
Wildner, M.W., see Ritter, M.M. **131**, 243
Wilson, H.M., see Mowat, B.F. **131**, 161

Yamashita, M., see Cercek, B. **131**, 59
Yamashita, S., see Yanagi, K. **131**, 49
Yanagi, K., S. Yamashita, H. Hiraoka, M. Ishigami, S. Kihara, K.-i. Hirano, N. Sakai, S. Nozaki, T. Funahashi, K. Kameda-Takemura, M. Kubo, K. Tokunaga, Y. Matsuzawa, Increased serum remnant lipoproteins in patients with apolipoprotein E7 (apo E_{Suita}) **131**, 49

Yasue, H., see Ota, Y. **131**, 195
Yeung, V.T.F., see Ko, G.T.C. **131**, 211
Yoo, H.J., K. Kozaki, M. Akishita, M. Watanabe, M. Eto, K. Nagano, N. Sudo, M. Hashimoto, S. Kim, M. Yoshizumi, K. Toba, Y. Ouchi, Augmented Ca^{2+} influx is involved in the mechanism of enhanced proliferation of cultured vascular smooth muscle cells from spontaneously diabetic Goto-Kakizaki rats **131**, 167
Yoshizumi, M., see Yoo, H.J. **131**, 167
Zheng, Z.-J., A.R. Sharrett, L.E. Chambless, W.D. Rosamond, F.J. Nieto, D.S. Sheps, A. Dobs, G.W. Evans, G. Heiss, Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: : the Atherosclerosis Risk in Communities (ARIC) Study **131**, 115
Zhu, J., see Cercek, B. **131**, 59
Zock, P.L., M.B. Katan, Butter, margarine and serum lipoproteins **131**, 7

ELSEVIER

Atherosclerosis 131 (1997) 270–271

ATHEROSCLEROSIS

Subject index

Volume 131 (1997)

Aged **131**, 137
Aging **131**, 43, 73
Alkenylacyl (plasmalogen) phosphatidylcholine **131**, 97
Anemia **131**, 127
Angiography **131**, 1
Angiotensin converting enzyme inhibitors **131**, 195
Angiotensin II **131**, 167
apo A4 polymorphisms **131**, 249
Apo E Phenotype **131**, 257
Apolipoprotein A2 **131**, 203
Apolipoprotein A1 **131**, 203
Apolipoprotein(a) **131**, 127
Apolipoprotein E **131**, 243, 257
Apolipoprotein E7 (apo E7) **131**, 49
Apoptosis **131**, 177
Arterial thrombosis **131**, 25
Arteriosclerosis **131**, 73
Aspirin **131**, 59
Atherosclerosis **131**, 79, 115, 141, 187
Atorvastatin **131**, 17

Balloon injury **131**, 59
Bay K 8644 **131**, 167
Bile acid **131**, 35
Biliary cholesterol **131**, 35
Biliary secretion **131**, 35
Bilirubin **131**, 107
Butter **131**, 7
Butylated hydroxytoluene (BHT) **131**, 237

Cardiovascular events **131**, 1
Cardiovascular risk factors **131**, 107, 211
Carotid artery **131**, 115
Cell proliferation **131**, 187
Children and young adults **131**, 107
Chinese **131**, 211
Cholesterol **131**, 127, 203, 229
Codon 360 **131**, 249
Codon 347 **131**, 249
Combined hyperlipidemia **131**, 17
Confocal immunofluorescence microscopy **131**, 67
Coronary arteries **131**, 177
Coronary heart disease **131**, 7, 115, 137
Cyclooxygenase **131**, 219
Cytokines **131**, 79
Cytosolic free calcium concentration **131**, 167

Diabetes **131**, 187
Diabetes mellitus **131**, 167
Diacyl phosphatidylethanolamine **131**, 97
Diet **131**, 25
Dietary fatty acids **131**, 7
Dyslipidemia **131**, 17

EBV-transformed lymphocytes **131**, 149
Eicosapentaenoic acid **131**, 219
Elastase inhibitors **131**, 73
Elastases **131**, 73
Elastin **131**, 73
Elastin peptides **131**, 73
Endothelium **131**, 195
Epidemiology **131**, 73

Familial hypercholesterolemia **131**, 67, 149
Familial LCAT deficiency **131**, 85
Fas/APO 1 **131**, 177
Fatty acid **131**, 25
Fibrinogen **131**, 211
Fish-eye disease **131**, 85
Fish oil **131**, 25
Flow cytometry **131**, 67
Free radical scavengers **131**, 195

Genetic polymorphism **131**, 243
Goto-Kakizaki rat **131**, 167

HDL **131**, 257
Hemodialysis **131**, 229
High density lipoprotein **131**, 1, 161
High density lipoprotein subfractions **131**, 161
HMG-CoA reductase **131**, 237
Human atherosclerosis **131**, 177

Humans **131**, 7
Hypercholesterolemia **131**, 17
Hypertriglyceridemia **131**, 17
Hypobetalipoproteinemia **131**, 135

IDL **131**, 257
Immunoabsorption **131**, 97
In situ hybridization **131**, 141
Intercellular adhesion molecule-1 **131**, 43
Intermediate density lipoprotein (IDL) **131**, 49
Ischemic heart disease **131**, 43
Isoforms **131**, 127

Ketoconazole **131**, 237

LCAT gene mutation **131**, 85
LDL **131**, 257
LDL-cholesterol concentration **131**, 243
Leukocytes **131**, 79
Linoleic acid **131**, 97
Lipid peroxide **131**, 219
Lipoprotein **131**, 229
Lipoprotein(a) **131**, 243
Lipoprotein cholesterol **131**, 7
Lipoproteins **131**, 127, 161
Lipoprotein-X **131**, 85
Low density lipoprotein **131**, 1, 161
Low density lipoprotein receptor **131**, 67, 149

Margarine **131**, 7
Midband **131**, 49
MTFHR gene **131**, 137
Mutations **131**, 67

Neointima **131**, 59, 141
NF-κB **131**, 59
Nitric oxide **131**, 195
Non-fasting lipid levels **131**, 249
North Indians **131**, 249

Oleic acid **131**, 97
Oxysterols **131**, 237

Peripheral arterial disease **131**, 115, 161
PGI_2 **131**, 219
Primary biliary cirrhosis **131**, 203
Proliferation **131**, 167
Proteoglycan **131**, 141

Race (black–white) **131**, 107
Reductase inhibitor **131**, 17
Remnant lipoprotein **131**, 49
Renal failure **131**, 85

Serum antioxidant **131**, 135
Smoking **131**, 195
Smooth muscle **131**, 59
Smooth muscle cells **131**, 187
Soluble adhesion molecules **131**, 43
Stroke **131**, 115
Syndecan-1 **131**, 141

β-Thalassemia **131**, 127
Transfection **131**, 67
Triglyceride **131**, 1
Triglyceride concentration **131**, 243
Triglycerides **131**, 229
Type III hyperlipoproteinemia **131**, 49
Tyrosylated HDL **131**, 35

Uremia **131**, 229

Vascular cell adhesion molecule-1 **131**, 43
Vascular smooth muscle cell **131**, 167
Vascular smooth muscle cells **131**, 219
Vegetable oil **131**, 25
Very low density lipoprotein (VLDL) **131**, 49
Vitamin deficiency **131**, 135
VLDL **131**, 257